Uncoupling of increased cellular oxidative stress and myocardial ischemia reperfusion injury by directed sarcolemma stabilization

Journal of Molecular and Cellular Cardiology

Volumn 67, Issue , 2014, Pages 26-37

  Martindale, Joshua J ^a   Metzger, Joseph M ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Dysferlin; Dystrophin; Ischemia; Membrane; Reperfusion; Sarcolemma

Indexed keywords

CELL MARKER; COPOLYMER; DYSTROPHIN; OXIDIZING AGENT; POLOXAMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL ASSAY; CELL DEATH; CELL MEMBRANE; CONTROLLED STUDY; EX VIVO STUDY; GENETIC MODEL; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE FIBER MEMBRANE; IN VIVO STUDY; LIPID PEROXIDATION; LOSS OF FUNCTION MUTATION; MEMBRANE STABILIZATION; MOLECULAR MECHANICS; MOUSE; NECROSIS; NONHUMAN; OXIDATIVE STRESS; OXIDATIVE STRESS UNCOUPLING; PRIORITY JOURNAL; PROTEIN DEPLETION; REPERFUSION INJURY; TARGET CELL;

CARDIAC TROPONIN I; COPOLYMER-BASED SARCOLEMMAL STABILIZATION; CSS; CTNI; DIHYDRODICHLOROFLUORESCEIN DIACETATE; DYSF KO; DYSFERLIN; DYSFERLIN KNOCKOUT MICE; DYSTROPHIN; DYSTROPHIN-DEFICIENT; H(2)DCFDA; I/R; ISCHEMIA; ISCHEMIA/REPERFUSION; LACTATE DEHYDROGENASE; LDH; MDX; MEMBRANE; MITOTRACKER GREEN; MTG; P188; P338; PEG; PEO; POLOXAMER 188; POLOXAMER 338; POLYETHYLENE GLYCOL 8000; POLYETHYLENE OXIDE; POLYPROPYLENE OXIDE; PPO; REPERFUSION; SARCOLEMMA; SI/R; SIMULATED ISCHEMIA/REPERFUSION; TETRAMETHYL RHODAMINE ESTER; TMRE;

ANIMALS; BIOLOGICAL ASSAY; CASPASE 3; CELL SURVIVAL; CELLS, CULTURED; MICE, INBRED C57BL; MODELS, CARDIOVASCULAR; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; OXIDATIVE STRESS; RATS; SARCOLEMMA;

EID: 84892834913     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2013.12.008     Document Type: Article

References (91)

1. Rosamond W., Flegal K., Friday G., Furie K., Go A., Greenlund K., et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007, 115:e69-e171.
2. Yellon D.M., Hausenloy D.J. Myocardial reperfusion injury. N Engl J Med 2007, 357:1121-1135.
3. Braunwald E. Unstable angina. A classification. Circulation 1989, 80:410-414.
4. Gill R.S., Pelletier J.S., LaBossiere J., Bigam D.L., Cheung P.Y. Therapeutic strategies to protect the immature newborn myocardium during resuscitation following asphyxia. Can J Physiol Pharmacol 2012, 90:689-695.
5. Hausenloy D.J., Yellon D.M. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest 2013, 123:92-100.
6. McCord J.M. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 1985, 312:159-163.
7. Smith R.C., Leung J.M., Mangano D.T. Postoperative myocardial ischemia in patients undergoing coronary artery bypass graft surgery. S.P.I. Research Group. Anesthesiology 1991, 74:464-473.
8. Armstrong S.C., Ganote C.E. Effects of 2,3-butanedione monoxime (BDM) on contracture and injury of isolated rat myocytes following metabolic inhibition and ischemia. J Mol Cell Cardiol 1991, 23:1001-1014.
9. Otani H., Matsuhisa S., Akita Y., Kyoi S., Enoki C., Tatsumi K., et al. Role of mechanical stress in the form of cardiomyocyte death during the early phase of reperfusion. Circ J 2006, 70:1344-1355.
10. Schlack W., Uebing A., Schafer M., Bier F., Schafer S., Piper H.M., et al. Regional contractile blockade at the onset of reperfusion reduces infarct size in the dog heart. Pflugers Arch-Eur J Physiol 1994, 428:134-141.
11. Siegmund B., Klietz T., Schwartz P., Piper H.M. Temporary contractile blockade prevents hypercontracture in anoxic-reoxygenated cardiomyocytes. Am J Physiol 1991, 260:H426-H435.
12. Voigtlander J., Leiderer R., Muhlbayer D., Habazettl H. Time-dependent efficacy of initial reperfusion with 2,3 butanedione monoxime (BDM) on release of cytosolic enzymes and ultrastructural damage in isolated hearts. Thorac Cardiovasc Surg 1999, 47:244-250.
13. Vanlangenakker N., Vanden Berghe T., Krysko D.V., Festjens N., Vandenabeele P. Molecular mechanisms and pathophysiology of necrotic cell death. Curr Mol Med 2008, 8:207-220.
14. Kang P.M., Haunstetter A., Aoki H., Usheva A., Izumo S. Morphological and molecular characterization of adult cardiomyocyte apoptosis during hypoxia and reoxygenation. Circ Res 2000, 87:118-125.
15. Abdallah Y., Kasseckert S.A., Iraqi W., Said M., Shahzad T., Erdogan A., et al. Interplay between Ca2+ cycling and mitochondrial permeability transition pores promotes reperfusion-induced injury of cardiac myocytes. J Cell Mol Med 2011, 15:2478-2485.
16. Nakayama H., Chen X., Baines C.P., Klevitsky R., Zhang X., Zhang H., et al. Ca2+- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure. J Clin Invest 2007, 117:2431-2444.
17. Ruiz-Meana M., Abellan A., Miro-Casas E., Garcia-Dorado D. Opening of mitochondrial permeability transition pore induces hypercontracture in Ca2+ overloaded cardiac myocytes. Basic Res Cardiol 2007, 102:542-552.
18. Burke A.P., Virmani R. Pathophysiology of acute myocardial infarction. Med Clin North Am 2007, 91:553-572.
19. Murphy E., Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev 2008, 88:581-609.
20. Whelan R.S., Kaplinskiy V., Kitsis R.N. Cell death in the pathogenesis of heart disease: mechanisms and significance. Annu Rev Physiol 2010, 72:19-44.
21. White H.D., Chew D.P. Acute myocardial infarction. Lancet 2008, 372:570-584.
22. Steinberg S.F. Oxidative stress and sarcomeric proteins. Circ Res 2013, 112:393-405.
23. Zima A.V., Blatter L.A. Redox regulation of cardiac calcium channels and transporters. Cardiovasc Res 2006, 71:310-321.
24. Chicco A.J., Sparagna G.C. Role of cardiolipin alterations in mitochondrial dysfunction and disease. Am J Physiol Cell Physiol 2007, 292:C33-C44.
25. Paradies G., Petrosillo G., Paradies V., Ruggiero F.M. Role of cardiolipin peroxidation and Ca2+ in mitochondrial dysfunction and disease. Cell Calcium 2009, 45:643-650.
26. Raedschelders K., Ansley D.M., Chen D.D. The cellular and molecular origin of reactive oxygen species generation during myocardial ischemia and reperfusion. Pharmacol Ther 2012, 133:230-255.
27. McCord J.M. Superoxide dismutase, lipid peroxidation, and bell-shaped dose response curves. Dose Response 2008, 6:223-238.
28. Sugamura K., Keaney J.F. Reactive oxygen species in cardiovascular disease. Free Radic Biol Med 2011, 51:978-992.
29. Kung G., Konstantinidis K., Kitsis R.N. Programmed necrosis, not apoptosis, in the heart. Circ Res 2011, 108:1017-1036.
30. Cheng C.Y., Wang J.Y., Kausik R., Lee K.Y., Han S. Nature of interactions between PEO-PPO-PEO triblock copolymers and lipid membranes: (II) role of hydration dynamics revealed by dynamic nuclear polarization. Biomacromolecules 2012, 13:2624-2633.
31. Maskarinec S.A., Wu G., Lee K.Y. Membrane sealing by polymers. Ann N Y Acad Sci 2005, 1066:310-320.
32. Yasuda S., Townsend D., Michele D.E., Favre E.G., Day S.M., Metzger J.M. Dystrophic heart failure blocked by membrane sealant poloxamer. Nature 2005, 436:1025-1029.
33. Wang J.Y., Marks J., Lee K.Y. Nature of interactions between PEO-PPO-PEO triblock copolymers and lipid membranes: (I) effect of polymer hydrophobicity on its ability to protect liposomes from peroxidation. Biomacromolecules 2012, 13:2616-2623.
34. Wu G., Majewski J., Ege C., Kjaer K., Weygand M.J., Lee K.Y. Lipid corralling and poloxamer squeeze-out in membranes. Phys Rev Lett 2004, 93:028101.
35. Townsend D., Turner I., Yasuda S., Martindale J., Davis J., Shillingford M., et al. Chronic administration of membrane sealant prevents severe cardiac injury and ventricular dilatation in dystrophic dogs. J Clin Invest 2010, 120:1140-1150.
36. Armstrong S.C., Latham C.A., Shivell C.L., Ganote C.E. Ischemic loss of sarcolemmal dystrophin and spectrin: correlation with myocardial injury. J Mol Cell Cardiol 2001, 33:1165-1179.
37. Kido M., Otani H., Kyoi S., Sumida T., Fujiwara H., Okada T., et al. Ischemic preconditioning-mediated restoration of membrane dystrophin during reperfusion correlates with protection against contraction-induced myocardial injury. Am J Physiol Heart Circ Physiol 2004, 287:H81-H90.
38. Kyoi S., Otani H., Hamano A., Matsuhisa S., Akita Y., Fujiwara H., et al. Dystrophin is a possible end-target of ischemic preconditioning against cardiomyocyte oncosis during the early phase of reperfusion. Cardiovasc Res 2006, 70:354-363.
39. Kyoi S., Otani H., Sumida T., Okada T., Osako M., Imamura H., et al. Loss of intracellular dystrophin: a potential mechanism for myocardial reperfusion injury. Circ J 2003, 67:725-727.
40. Rodriguez M., Cai W.J., Kostin S., Lucchesi B.R., Schaper J. Ischemia depletes dystrophin and inhibits protein synthesis in the canine heart: mechanisms of myocardial ischemic injury. J Mol Cell Cardiol 2005, 38:723-733.
41. Towbin J.A., Vatta M. Myocardial infarction, viral infection, and the cytoskeleton final common pathways of a common disease?. J Am Coll Cardiol 2007, 50:2215-2217.
42. Yoshida H., Takahashi M., Koshimizu M., Tanonaka K., Oikawa R., Toyo-oka T., et al. Decrease in sarcoglycans and dystrophin in failing heart following acute myocardial infarction. Cardiovasc Res 2003, 59:419-427.
43. Wang X., Xie W., Zhang Y., Lin P., Han L., Han P., et al. Cardioprotection of ischemia/reperfusion injury by cholesterol-dependent MG53-mediated membrane repair. Circ Res 2010, 107:76-83.
44. Han R., Bansal D., Miyake K., Muniz V.P., Weiss R.M., McNeil P.L., et al. Dysferlin-mediated membrane repair protects the heart from stress-induced left ventricular injury. J Clin Invest 2007, 117:1805-1813.
45. Dudley R.W., Danialou G., Govindaraju K., Lands L., Eidelman D.E., Petrof B.J. Sarcolemmal damage in dystrophin deficiency is modulated by synergistic interactions between mechanical and oxidative/nitrosative stresses. Am J Pathol 2006, 168:1276-1287. [quiz 404-5].
46. Dudley R.W., Khairallah M., Mohammed S., Lands L., Des Rosiers C., Petrof B.J. Dynamic responses of the glutathione system to acute oxidative stress in dystrophic mouse (mdx) muscles. Am J Physiol Regul Integr Comp Physiol 2006, 291:R704-R710.
47. Metzger J.M., Michele D.E., Rust E.M., Borton A.R., Westfall M.V. Sarcomere thin filament regulatory isoforms. Evidence of a dominant effect of slow skeletal troponin I on cardiac contraction. J Biol Chem 2003, 278:13118-13123.
48. Das A., Xi L., Kukreja R.C. Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol Chem 2005, 280:12944-12955.
49. Diaz R.J., Wilson G.J. Studying ischemic preconditioning in isolated cardiomyocyte models. Cardiovasc Res 2006, 70:286-296.
50. Methods of enzymatic analysis 1983, Weinheim, Deerfield Beach, Florida. 3rd ed.
51. Bi G.Q., Alderton J.M., Steinhardt R.A. Calcium-regulated exocytosis is required for cell membrane resealing. J Cell Biol 1995, 131:1747-1758.
52. Elmore S.P., Nishimura Y., Qian T., Herman B., Lemasters J.J. Discrimination of depolarized from polarized mitochondria by confocal fluorescence resonance energy transfer. Arch Biochem Biophys 2004, 422:145-152.
53. Ruiz-Meana M., Abellan A., Miro-Casas E., Agullo E., Garcia-Dorado D. Role of sarcoplasmic reticulum in mitochondrial permeability transition and cardiomyocyte death during reperfusion. Am J Physiol Heart Circ Physiol 2009, 297:H1281-H1289.
54. Drummen G.P., Van Liebergen L.C., Den Kamp JA Op, Post J.A. C11-BODIPY(581/591), an oxidation-sensitive fluorescent lipid peroxidation probe: (micro)spectroscopic characterization and validation of methodology. Free Radic Biol Med 2002, 33:473-490.
55. Williamson C.L., Dabkowski E.R., Dillmann W.H., Hollander J.M. Mitochondria protection from hypoxia/reoxygenation injury with mitochondria heat shock protein 70 overexpression. Am J Physiol Heart Circ Physiol 2008, 294:H249-H256.
56. Prosser B.L., Ward C.W., Lederer W.J. X-ROS signaling: rapid mechano-chemo transduction in heart. Science 2011, 333:1440-1445.
57. Iribe G., Ward C.W., Camelliti P., Bollensdorff C., Mason F., Burton R.A., et al. Axial stretch of rat single ventricular cardiomyocytes causes an acute and transient increase in Ca2+ spark rate. Circ Res 2009, 104:787-795.
58. Herron T.J., Devaney E., Mundada L., Arden E., Day S., Guerrero-Serna G., et al. Ca2+-independent positive molecular inotropy for failing rabbit and human cardiac muscle by alpha-myosin motor gene transfer. FASEB J 2010, 24:415-424.
59. Fedorov V.V., Lozinsky I.T., Sosunov E.A., Anyukhovsky E.P., Rosen M.R., Balke C.W., et al. Application of blebbistatin as an excitation-contraction uncoupler for electrophysiologic study of rat and rabbit hearts. Heart Rhythm 2007, 4:619-626.
60. Day S.M., Westfall M.V., Fomicheva E.V., Hoyer K., Yasuda S., La Cross N.C., et al. Histidine button engineered into cardiac troponin I protects the ischemic and failing heart. Nat Med 2006, 12:181-189.
61. Barnabei M.S., Palpant N.J., Metzger J.M. Influence of genetic background on ex vivo and in vivo cardiac function in several commonly used inbred mouse strains. Physiol Genomics 2010, 42A:103-113.
62. Dikalov S., Griendling K.K., Harrison D.G. Measurement of reactive oxygen species in cardiovascular studies. Hypertension 2007, 49:717-727.
63. Kuznetsov A.V., Kehrer I., Kozlov A.V., Haller M., Redl H., Hermann M., et al. Mitochondrial ROS production under cellular stress: comparison of different detection methods. Anal Bioanal Chem 2011, 400:2383-2390.
64. Winterbourn C.C. The challenges of using fluorescent probes to detect and quantify specific reactive oxygen species in living cells. Biochim Biophys Acta 2013, 1840:730-738.
65. Bolli R., Becker L., Gross G., Mentzer R., Balshaw D., Lathrop D.A., et al. Myocardial protection at a crossroads: the need for translation into clinical therapy. Circ Res 2004, 95:125-134.
66. Thygesen K., Alpert J.S., Jaffe A.S., Simoons M.L., Chaitman B.R., White H.D., et al. Third universal definition of myocardial infarction. Nat Rev Cardiol 2012, 9:620-633.
67. Thygesen K., Alpert J.S., Jaffe A.S., Simoons M.L., Chaitman B.R., White H.D., et al. Third universal definition of myocardial infarction. Circulation 2012, 126:2020-2035.
68. Garcia-Dorado D., Theroux P., Duran J.M., Solares J., Alonso J., Sanz E., et al. Selective inhibition of the contractile apparatus. A new approach to modification of infarct size, infarct composition, and infarct geometry during coronary artery occlusion and reperfusion. Circulation 1992, 85:1160-1174.
69. Koyama T., Boston D., Ikenouchi H., Barry W.H. Survival of metabolically inhibited ventricular myocytes is enhanced by inhibition of rigor and SR Ca2+ cycling. Am J Physiol 1996, 271:H643-H650.
70. Schluter K.D., Schwartz P., Siegmund B., Piper H.M. Prevention of the oxygen paradox in hypoxic-reoxygenated hearts. Am J Physiol 1991, 261:H416-H423.
71. Baines C.P., Kaiser R.A., Purcell N.H., Blair N.S., Osinska H., Hambleton M.A., et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 2005, 434:658-662.
72. Nakagawa T., Shimizu S., Watanabe T., Yamaguchi O., Otsu K., Yamagata H., et al. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 2005, 434:652-658.
73. Brookes P.S., Yoon Y., Robotham J.L., Anders M.W., Sheu S.S. Calcium, ATP, and ROS: a mitochondrial love-hate triangle. Am J Physiol Cell Physiol 2004, 287:C817-C833.
74. Ladue J.S., Wroblewski F., Karmen A. Serum glutamic oxaloacetic transaminase activity in human acute transmural myocardial infarction. Science 1954, 120:497-499.
75. Wroblewski F., Ruegsegger P., Ladue J.S. Serum lactic dehydrogenase activity in acute transmural myocardial infarction. Science 1956, 123:1122-1123.
76. Camilleri J.P., Joseph D., Amat D., Fabiani J.N. Impaired sarcolemmal membrane permeability in reperfused ischemic myocardium. Ultrastructural tracer study. Virchows Arch A Pathol Anat Histol 1980, 388:69-76.
77. Harper I.S., Lochner A. Sarcolemmal integrity during ischaemia and reperfusion of the isolated rat heart. Basic Res Cardiol 1989, 84:208-226.
78. Hearse D.J., Humphrey S.M., Nayler W.G., Slade A., Border D. Ultrastructural damage associated with reoxygenation of the anoxic myocardium. J Mol Cell Cardiol 1975, 7:315-324.
79. Jennings R.B., Reimer K.A., Steenbergen C. Myocardial ischemia revisited. The osmolar load, membrane damage, and reperfusion. J Mol Cell Cardiol 1986, 18:769-780.
80. Steenbergen C., Hill M.L., Jennings R.B. Volume regulation and plasma membrane injury in aerobic, anaerobic, and ischemic myocardium in vitro. Effects of osmotic cell swelling on plasma membrane integrity. Circ Res 1985, 57:864-875.
81. Khaw B.A., Torchilin V.P., Vural I., Narula J. Plug and seal: prevention of hypoxic cardiocyte death by sealing membrane lesions with antimyosin-liposomes. Nat Med 1995, 1:1195-1198.
82. Khudairi T., Khaw B.A. Preservation of ischemic myocardial function and integrity with targeted cytoskeleton-specific immunoliposomes. J Am Coll Cardiol 2004, 43:1683-1689.
83. Torchilin V.P., Narula J., Halpern E., Khaw B.A. Poly(ethylene glycol)-coated anti-cardiac myosin immunoliposomes: factors influencing targeted accumulation in the infarcted myocardium. Biochim Biophys Acta 1996, 1279:75-83.
84. Bates F.S., Hillmyer M.A., Lodge T.P., Bates C.M., Delaney K.T., Fredrickson G.H. Multiblock polymers: panacea or Pandora's box?. Science 2012, 336:434-440.
85. Frey S.L., Zhang D., Carignano M.A., Szleifer I., Lee K.Y. Effects of block copolymer's architecture on its association with lipid membranes: experiments and simulations. J Chem Phys 2007, 127:114904.
86. Weisleder N., Takizawa N., Lin P., Wang X., Cao C., Zhang Y., et al. Recombinant MG53 protein modulates therapeutic cell membrane repair in treatment of muscular dystrophy. Sci Transl Med 2012, 4:139ra85.
87. Song R., Peng W., Zhang Y., Lv F., Wu H.K., Guo J., et al. Central role of E3 ubiquitin ligase MG53 in insulin resistance and metabolic disorders. Nature 2013, 494:375-379.
88. Effects of RheothRx on mortality, morbidity, left ventricular function, and infarct size in patients with acute myocardial infarction Collaborative Organization for RheothRx Evaluation (CORE). Circulation 1997, 96:192-201.
89. Maynard C., Swenson R., Paris J.A., Martin J.S., Hallstrom A.P., Cerqueira M.D., et al. Randomized, controlled trial of RheothRx (poloxamer 188) in patients with suspected acute myocardial infarction. RheothRx in Myocardial Infarction Study Group. Am Heart J 1998, 135:797-804.
90. Schaer G.L., Spaccavento L.J., Browne K.F., Krueger K.A., Krichbaum D., Phelan J.M., et al. Beneficial effects of RheothRx injection in patients receiving thrombolytic therapy for acute myocardial infarction. Results of a randomized, double-blind, placebo-controlled trial. Circulation 1996, 94:298-307.
91. Schwartz Longacre L., Kloner R.A., Arai A.E., Baines C.P., Bolli R., Braunwald E., et al. New horizons in cardioprotection: recommendations from the 2010 National Heart, Lung, and Blood Institute Workshop. Circulation 2011, 124:1172-1179.